drugset
drugset / Trial / NCT02749799

Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis

NCT02749799 ↗

Phase 4 Completed 45 enrolled Primus Pharmaceuticals Prosoft Clinical · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.

Timeline

Start
2016-02
Primary completion
2016-07
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject betamethasone dipropionate Small molecule 0.05 % Topical

Indications

psoriasis